AGEN - Agenus Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.9500
0.0000 (0.00%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.9500
Open2.9200
Bid0.0000 x 4000
Ask0.0000 x 4000
Day's Range2.8800 - 2.9900
52 Week Range1.5400 - 3.8800
Volume975,394
Avg. Volume1,190,684
Market Cap396.064M
Beta (3Y Monthly)1.87
PE Ratio (TTM)N/A
EPS (TTM)-0.7460
Earnings DateJul 28, 2017 - Jul 31, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.00
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEvents5 days ago

    Edited Transcript of AGEN earnings conference call or presentation 9-May-19 12:30pm GMT

    Q1 2019 Agenus Inc Earnings Call

  • Agenus (AGEN) Q1 Earnings Beat Estimates, Revenues Miss
    Zacks9 days ago

    Agenus (AGEN) Q1 Earnings Beat Estimates, Revenues Miss

    Agenus' (AGEN) earnings beat estimates in the first quarter of 2019. Sales marginally miss the same.

  • Agenus Inc (AGEN) Q1 2019 Earnings Call Transcript
    Motley Fool10 days ago

    Agenus Inc (AGEN) Q1 2019 Earnings Call Transcript

    AGEN earnings call for the period ending March 31, 2019.

  • Agenus (AGEN) Surpasses Q1 Earnings Estimates
    Zacks11 days ago

    Agenus (AGEN) Surpasses Q1 Earnings Estimates

    Agenus (AGEN) delivered earnings and revenue surprises of 140.00% and -4.65%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press11 days ago

    Agenus: 1Q Earnings Snapshot

    The Lexington, Massachusetts-based company said it had net income of 12 cents per share. The biotechnology company posted revenue of $8.6 million in the period. The company's shares closed at $2.66. A ...

  • PR Newswire11 days ago

    Agenus Reports First Quarter 2019 Financial Results and Provides Corporate Update

    - Gilead partnership yields $150M & first milestone of $7.5M - Exceeding enrollment targets in BLA path CTLA-4 & PD-1 trials - Second generation CTLA-4 in the clinic; combos and data planned in 2019 - ...

  • ACCESSWIRE11 days ago

    Agenus, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 9, 2019 / Agenus, Inc. (NASDAQ: AGEN ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 9, 2019 at 8:30 AM Eastern Time. ...

  • PR Newswire16 days ago

    Agenus to Report First Quarter 2019 Financial Results on May 9, 2019 and Host Conference Call and Webcast

    LEXINGTON, Mass. , May 3, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies ...

  • Imagine Owning Agenus (NASDAQ:AGEN) And Wondering If The 41% Share Price Slide Is Justified
    Simply Wall St.27 days ago

    Imagine Owning Agenus (NASDAQ:AGEN) And Wondering If The 41% Share Price Slide Is Justified

    For many investors, the main point of stock picking is to generate higher returns than the overall market. But if you try your hand at stock picking, your risk returning less than the market. We regret to report that long ter...

  • Why Is Agenus (AGEN) Down 13% Since Last Earnings Report?
    Zackslast month

    Why Is Agenus (AGEN) Down 13% Since Last Earnings Report?

    Agenus (AGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Gilead Files sNDA for Label Expansion of HIV Therapy Descovy
    Zackslast month

    Gilead Files sNDA for Label Expansion of HIV Therapy Descovy

    Gilead (GILD) submits sNDA to the FDA for label expansion of Descovy as PrEP to reduce the risk of sexually acquired HIV-1 infection.

  • PR Newswire2 months ago

    Agenus Begins Dosing with Next-Gen Anti-CTLA-4 Antibody

    LEXINGTON, Mass., April 2, 2019 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology company with a pipeline of immune-modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies1, today announced that the first patient was dosed in the clinical trial of its next-generation anti-CTLA-4 antibody (AGEN1181). AGEN1181, a novel 'Fc engineered' antibody with potential for enhanced anti-tumor functions, is specifically designed to boost cancer killing immune cells and deplete cells that block the activity of these cancer killing cells. The first patient in the trial was dosed by Dr. Steven J. O'Day, M.D., Executive Director of the John Wayne Cancer Institute & Cancer Clinic, and a pioneer in delivering immune therapies to patients with cancer.  Dr. O'Day's pivotal work has led to the approvals of commercial antibodies targeting CTLA-4 and PD-1.  "AGEN1181 represents an important next-generation breakthrough with its potential for enhanced immune activation and tumor fighting abilities," said Dr. O'Day.

  • PR Newswire2 months ago

    Agenus Announces Clinical Appointments

    LEXINGTON, Mass., March 21, 2019 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies1, announced new leadership appointments as its CTLA-4 and PD-1 programs advance towards a planned BLA filing in 2020. Dr. Manuel Hidalgo, MD, PhD, joins as Strategic Advisor. Dr. Hidalgo, an internationally renowned oncologist, has led clinical development of more than 50 novel anticancer agents including erlotinib, temsirolimus and nab-paclitaxel, which are FDA approved for the treatment of cancer.

  • 3 Top Growth Stocks to Buy Right Now
    Motley Fool2 months ago

    3 Top Growth Stocks to Buy Right Now

    Surprise! This retailer and lesser-known biotechnology company could be potential multibaggers.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of AGEN earnings conference call or presentation 14-Mar-19 12:30pm GMT

    Q4 2018 Agenus Inc Earnings Call

  • Agenus Wins $7.5M Milestone Payment From Gilead, Stock Up
    Zacks2 months ago

    Agenus Wins $7.5M Milestone Payment From Gilead, Stock Up

    Agenus (AGEN) gets a $7.5-million milestone payment from Gilead following the FDA acceptance of the company's IND filing for AGEN1423. Shares rise.

  • Agenus Inc (AGEN) Q4 2018 Earnings Conference Call Transcript
    Motley Fool2 months ago

    Agenus Inc (AGEN) Q4 2018 Earnings Conference Call Transcript

    AGEN earnings call for the period ending December 31, 2018.

  • Agenus (AGEN) Reports Q4 Loss, Lags Revenue Estimates
    Zacks2 months ago

    Agenus (AGEN) Reports Q4 Loss, Lags Revenue Estimates

    Agenus (AGEN) delivered earnings and revenue surprises of -42.86% and -19.63%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    Agenus: 4Q Earnings Snapshot

    On a per-share basis, the Lexington, Massachusetts-based company said it had a loss of 40 cents. The biotechnology company posted revenue of $5.4 million in the period. For the year, the company reported ...

  • PR Newswire2 months ago

    Agenus Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update

    - Gilead collaboration results in cash infusion of $150M ; first milestone payment of $7.5M triggered - CTLA-4 & PD-1 trials are accruing for planned BLA filing as early as 2020 - Next-Gen CTLA-4 advancing ...

  • PR Newswire2 months ago

    Agenus Milestone Triggers $7.5M Payment from Gilead

    LEXINGTON, Mass., March 13, 2019 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies1, announced today that the FDA has accepted the company's IND filing for AGEN1423 - a milestone in its partnership with Gilead Sciences, Inc. This milestone triggered a cash payment of $7.5M. Agenus is eligible to receive additional milestone payments in 2019 and beyond.

  • Gilead Reports Positive Data on HIV Drugs Biktarvy & Descovy
    Zacks2 months ago

    Gilead Reports Positive Data on HIV Drugs Biktarvy & Descovy

    Gilead (GILD) presents encouraging data on two leading HIV regimens, Bikatrvy and Descovy.

  • The 3 Oldest Members of Biotech's Billion-Burned Club
    Motley Fool3 months ago

    The 3 Oldest Members of Biotech's Billion-Burned Club

    These biopharmaceutical startups have been losing their investors' money for decades.

  • GlobeNewswire3 months ago

    Analysis: Positioning to Benefit within Micron Technology, Caterpillar, Agenus, Fossil Group, Marathon Petroleum, and Geo Group — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Feb. 20, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.

  • PR Newswire3 months ago

    Agenus Launches First Asset-Backed Digital-Security Offering in Healthcare

    LEXINGTON, Mass., Feb. 19, 2019 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology (I-O) company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies1, announced today the launch of its Biotech Electronic Security Token (BEST), the first digital-security offering in healthcare. Agenus will host a conference call and live audio webcast today at 11:00 a.m. ET to discuss the launch of BEST and provide a full briefing on the digital security and offering process. Agenus previously announced that BEST is designed to be an innovative and transformative way to finance drug development by increasing liquidity, minimizing dilution, and improving capital allocation.  BEST is envisioned as a way to democratize financing through targeted investments for specific therapeutic drug products.